NovaBridge’s ophthalmology subsidiary, Visara, has assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacturing, and commercialization across Greater China, Singapore, South Korea, and select Southeast Asian markets. Everest will assume all payment obligations under the underlying AskGene license and reimburse Visara for any upfront already paid. VIS-101, a bifunctional biologic targeting VEGF-A and Ang-2, is completing a randomized, dose-ranging phase 2 study in China and is expected to be phase-3-ready in 2026. In a parallel governance move, NovaBridge added Everest Medicines’ president and chief financial officer, Ian Woo, to its board.
The transaction is a clear readout on strategy: NovaBridge is leaning into a capital-light, regionally partnered path to advance a second-in-class, potentially best-in-class retinal asset, while Everest uses business development to catalyze entry into ophthalmology with a late-stage candidate. The dual-pronged tactic reduces NovaBridge’s cash burn in Asia and accelerates regional execution, but it also raises the bar on differentiation. In a market where the VEGF backbone is entrenched and dual-pathway approaches are gaining share, “more durable” must translate into measurable reductions in injection burden and clinic visits to command premium access.
Why this matters now is straightforward. Asia’s aging populations are expanding the pool of patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, while retina clinic capacity remains constrained. Payers across China, Korea, and Singapore are increasingly data-driven, expecting durability claims to be proven beyond controlled trials. Real-world evidence showing extended dosing intervals without compromising vision outcomes will be pivotal for NRDL inclusion in China and cost-effectiveness decisions in Korea. For HCPs, head-to-head or pragmatic data versus established anti-VEGFs and dual-pathway competitors will influence adoption far more than class-based arguments. For patients, fewer injections and sustained vision gains are the tangible outcomes that will matter.
Commercially, Everest inherits the heavy lift: ophthalmic biologic CMC scale-up, regulatory strategy for multi-indication labels, and evidence packages tuned to regional HTA dynamics. Price competition from incumbents and biosimilars is already pressuring anti-VEGF margins; any premium positioning for VIS-101 will have to be underpinned by clear clinic throughput benefits and robust treat-and-extend performance. A segmented launch strategy that prioritizes centers of excellence and early real-world registries could help bridge from phase 2 to market uptake. Competitively, global dual-pathway agents are setting the reference point on durability; absent direct comparisons, noninferiority with superior dosing intervals or retreatment rates may be the minimum bar for persuasive positioning.
For NovaBridge and Visara, retaining rights outside the partnered Asian territories preserves option value. A 2026 phase 3 start sets a tight clock to finalize global study design, align on endpoints that resonate with payers, and plan manufacturing controls specific to intravitreal biologics. The addition of a cross-company finance executive to NovaBridge’s board signals tighter alignment on capital markets and partnering pathways, but it also puts a spotlight on governance discipline as the asset advances toward registrational work.
The next signal to watch is the readout of the ongoing China phase 2 and the resulting phase 3 blueprint. If Everest backs a head-to-head durability program and secures early real-world pilots aligned to access milestones, VIS-101 could credibly challenge for share in Asia’s high-volume retina market. The broader question for the industry is whether this regional licensing model becomes the default for ophthalmology assets: can capital-efficient partnerships deliver the differentiated evidence payers now demand, or will only fully integrated players have the throughput to win in a durability-first retina landscape?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
